EUVIMEDEUVIMED entdecken
Crossref

Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects

Cheng Shi iD, Yanping Zhao, Han Huang, Jiaxu Zhou, Dehua Lu, Yanming Chen, Weiping Lyu, Zhenming Liu iD, Hongjun Wang, Liangren Zhang iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Cheng Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Antineoplastic Agents, Drug Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, State Key Laboratory of Pharmaceutical Biotechnology, Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Src homology-2-containing protein tyrosine phosphatase (PTP) 2 (SHP2) is a pivotal PTP that modulates key cellular processes including proliferation, differentiation, and migration. Its overexpression is implicated in the pathogenesis of various malignancies, highlighting the need for effective SHP2 inhibitors. Herein, we report the design and synthesis of a novel series of thiazolo[5,4-b]pyridine and imidazo[1,2-c]pyrimidine derivatives as SHP2 allosteric inhibitors identified through active fragment splicing. The synthesized compounds exhibited potent SHP2 inhibition, with IC50 values ranging from 9.0 to 34.5 nM. Notably, compound B8 demonstrated superior potency, with an IC50 of 0.04 μM for p-ERK modulation. Compound B8 also displayed favorable drug-like properties and significant antitumor activity in a KYSE520 xenograft mouse model, underscoring its potential as a lead candidate for further development. Our findings provide a foundation for the advancement of SHP2-targeted therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 11Antineoplastic AgentsDrug DesignHumansAnimalsMiceAllosteric RegulationStructure-Activity RelationshipCell Line, TumorEnzyme InhibitorsCell ProliferationXenograft Model Antitumor AssaysPyrimidinesMice, NudeDrug Screening Assays, AntitumorMolecular Structure

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 11Antineoplastic AgentsEnzyme InhibitorsPTPN11 protein, humanPyrimidines

Autor:innen und Institutionen

  • State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
  • Beijing Tide Pharmaceutical Co., Ltd., Beijing 100176, China.
  • State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.

ORCID-Profile: Cheng Shi, Zhenming Liu, Liangren Zhang

Förderung

  • Natural Science Foundation of Beijing Municipality
  • State Key Laboratory of Pharmaceutical Biotechnology
  • Guangdong Basic and Applied Basic Research Foundation

Zitieren

APA

Shi, C., Zhao, Y., Huang, H., Zhou, J., Lu, D., Chen, Y., Lyu, W., Liu, Z., Wang, H., & Zhang, L. (2025). Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02100

Vancouver

Shi C, Zhao Y, Huang H, Zhou J, Lu D, Chen Y, et al. Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02100

BibTeX
@article{Shi2025,
  author = {Shi, Cheng and Zhao, Yanping and Huang, Han and Zhou, Jiaxu and Lu, Dehua and Chen, Yanming and Lyu, Weiping and Liu, Zhenming and Wang, Hongjun and Zhang, Liangren},
  title = {Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02100}
}
Kostenlos starten →